Search

Iroxanadine

It induces phosphorylation of p38 SAPK, which plays an important role in EC homeostasis. endothelial cell (EC). … EC function plays a central role in vascular diseases (e.g. atherosclerosis, restenosis, diabetic angiopathies, microvascular angina, peripheral arterial disease).

Higenamine

Higenamine is under investigation in clinical trial NCT01451229 (Pharmacokinetics and Pharmacodynamics of Higenamine in Chinese Healthy Subjects).

8-chlorotheophylline

Its main use is in combination with [Diphenhydramine] as the antiemetic drug [Dimenhydrinate]. … Because adenosine causes a decrease in neuronal firing, blockade of the adenosine receptor causes the reverse effect resulting in excitation.

XL820

XL820 is investigated for use/treatment in solid tumors. XL820 is a solid. … XL820 exhibits dose-dependent growth inhibition in models of breast carcinoma, gliomas and leukemia.

TGAAC09

It was under investigation in clinical trials NCT00482027 and NCT00888446 for the treatment of HIV Infection. … tgAAC09 is an investigational vaccine that utilizes an AAV vector to deliver genes that encode HIV proteins.

ANA971

ANA971 resulted in higher levels of isatoribine in the blood than were present after oral administration of isatoribine itself. … ANA971, an orally administered prodrug of isatoribine. Isatoribine is a nucleoside analog in development for the treatment of chronic hepatitis C virus (HCV) infection.

TAS-108

Contusugene ladenovec

INGN 201(Advexin) is a replication-impaired adenoviral vector that carries the p53 gene, has been evaluated in both preclinical and clinical trials. … Advexin is a well-tolerated and efficacious treatment for numerous cancers, both as monotherapy and in combination with radiation and/or chemotherapy agents.

FX06

FX06 has proven safe in acute and subchronic toxicological studies and recently entered clinical development. It is being developed by Fibrex Medical Inc. … FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells.

Nimesulide

Due to concerns about the risk of hepatotoxicity, nimesulide has been withdrawn from market in many countries. … Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old.